• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYInsights
  • MYBoard
  • Strategy & Consulting
Select Page

Quadruplet regimens for patients with newly diagnosed multiple myeloma: A systematic review and meta-analysis

by | Oct 1, 2024 | Publications

Blood Adv. 2024 Sep 30:bloodadvances.2024014139. doi: 10.1182/bloodadvances.2024014139. Online ahead of print. ABSTRACT Quadruplet regimens (anti-CD38 monoclonal antibodies (mAbs) with proteosome inhibitor (PI) and immunomodulatory (IMID) drugs) are increasingly being...

Multiple myeloma clinical trials exclude patients with the highest-risk disease: a systematic review of trial exclusion criteria

by | Sep 24, 2024 | Publications

Leuk Lymphoma. 2024 Sep 24:1-10. doi: 10.1080/10428194.2024.2395440. Online ahead of print. ABSTRACT Patients with certain subsets of multiple myeloma continue to have poor outcomes and are in need of novel treatment approaches. Strict eligibility criteria for...

Risk assessment and clinical implications of COVID-19 in multiple myeloma patients: A systematic review and meta-analysis

by | Sep 18, 2024 | Publications

PLoS One. 2024 Sep 6;19(9):e0308463. doi: 10.1371/journal.pone.0308463. eCollection 2024. ABSTRACT INTRODUCTION: Patients with multiple myeloma (MM) face heightened infection susceptibility, particularly severe risks from COVID-19. This study, the first systematic...

Efficacy of daratumumab on multiple myeloma patients with renal insufficiency: a systematic review and meta-analysis

by | Sep 18, 2024 | Publications

Hematology. 2024 Dec;29(1):2399430. doi: 10.1080/16078454.2024.2399430. Epub 2024 Sep 9. ABSTRACT BACKGROUND: Renal insufficiency (RI) is a key factor affecting the prognosis of multiple myeloma (MM) patients. Because the benefit of daratumumab for treating MM...

Modest survival benefits of autologous stem cell transplantation in multiple myeloma with renal impairment: a critical appraisal of the pre-antibody era

by | Sep 18, 2024 | Publications

Clin Exp Med. 2024 Sep 9;24(1):215. doi: 10.1007/s10238-024-01481-2. ABSTRACT The benefit of high-dose melphalan followed by autologous hematopoietic stem cell transplantation (HDM-ASCT) for multiple myeloma (MM) patients with renal insufficiency (RI) is debated. A...

Meta-analysis of effectiveness and safety of proteasome inhibitor-dependent maintenance treatment for multiple myeloma a systematic review

by | Sep 18, 2024 | Publications

Heliyon. 2024 Aug 13;10(16):e36311. doi: 10.1016/j.heliyon.2024.e36311. eCollection 2024 Aug 30. ABSTRACT BACKGROUND: Even with significant advancements, treating multiple myeloma (MM) remains difficult. At present, the main treatment methods include combined...
« Older Entries
Next Entries »

Recent Content

  • Multiple myeloma incidence, transplant utilization, and mortality- impact of social vulnerability
  • Correction: Impact of daratumumab refractoriness on clinical outcomes following CAR T-cell therapy for relapsed refractory multiple myeloma
  • Treatment Outcomes of Multiple Myeloma in Developing Countries: A Systematic Review and Meta-Analysis
  • Automated radiomics model for prediction of therapy response and minimal residual disease from baseline MRI in multiple myeloma
  • Prognostic and clinicopathological value of prognostic nutritional index in patients with multiple myeloma: a meta-analysis
  • Daratumumab plus lenalidomide maintenance in newly diagnosed multiple myeloma after transplant: AURIGA subgroup analyses
  • Randomized Phase 3 study of pomalidomide cyclophosphamide dexamethasone versus pomalidomide dexamethasone in relapse or refractory myeloma: an Asian Myeloma Network study (AMN003)
  • (no title)
  • The risk of second primary malignancies in patients receiving T-cell directed therapies for multiple myeloma: a systematic review
  • (no title)
  • Facebook
  • X
  • Instagram
©2016-2025 MYELOMA360 & Connect BioMed
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT